EP Patent

EP3489224A1 — Mirabegron prodrugs

Assigned to Alfred E Tiefenbacher GmbH and Co KG · Expires 2019-05-29 · 7y expired

What this patent protects

The present invention relates to prodrugs of Mirabegron, their preparation and use in therapy.

USPTO Abstract

The present invention relates to prodrugs of Mirabegron, their preparation and use in therapy.

Drugs covered by this patent

Myrbetriq (MIRABEGRON) · Apgdi

Patent Metadata

Patent number: EP3489224A1
Jurisdiction: EP
Classification: —
Expires: 2019-05-29
Drug substance claim: No
Drug product claim: No
Assignee: Alfred E Tiefenbacher GmbH and Co KG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.